Financials in USD. Standardized financial statements.
A compact view of how Virax Biolabs Group Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $6,331 | $156,419 | $8,561 | $0 | $123,820 | $99,876 |
| Revenue Growth? | -96.0% | +1727.1% | 0.0% | -100.0% | +24.0% | 0.0% |
| Cost of Revenue? | $59,398 | $105,829 | $9,926 | $0 | $133,254 | $54,127 |
| Gross Profit? | -$53,067 | $50,590 | -$1,365 | $0 | -$9,434 | $45,749 |
| Gross Margin? | -838.2% | +32.3% | -15.9% | 0.0% | -7.6% | +45.8% |
| Operating Expenses? | $6.11M | $6.55M | $5.73M | $1.73M | $635,104 | $696,993 |
| Operating Income? | -$6.16M | -$6.50M | -$5.73M | -$1.73M | -$644,540 | -$651,244 |
| EBITDA? | -$5.80M | -$6.61M | -$5.44M | -$750 | $0 | $2,470 |
| Income Before Tax | -$6.20M | -$6.74M | -$5.46M | -$1.75M | -$672,915 | -$739,464 |
| Income Tax Expense | -$136,661 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$6.06M | -$6.73M | -$5.46M | -$1.71M | -$650,984 | -$801,131 |
| EPS? | $-1.96 | $-3.36 | $-5.13 | $-1.50 | $-0.57 | $-0.70 |
| Diluted EPS? | $-1.95 | $-3.36 | $-5.13 | $-1.50 | $-0.57 | $-0.70 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality